A simple method for identifying bone marrow mesenchymal stromal cells with a high immunosuppressive potential

Cytotherapy

Volumn 13, Issue 5, 2011, Pages 523-527

  Rizzo, Roberta ^a   Lanzoni, Giacomo ^b   Stignani, Marina ^a   Campioni, Diana ^c   Alviano, Francesco ^b   Ricci, Francesca ^d   Tazzari, Pier Luigi ^d   Melchiorri, Loredana ^a   Scalinci, Sergio Zaccaria ^d   Cuneo, Antonio ^c   Bonsi, Laura ^b   Lanza, Francesco ^e   Bagnara, Gian Paolo ^b   Baricordi, Olavio R ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e CREMONA HOSPITAL   (Italy)

Author keywords

graft versus host disease; HLA G; interleukin 10; mesenchymal stromal cells

Indexed keywords

HLA G ANTIGEN; PHYTOHEMAGGLUTININ; RECOMBINANT INTERLEUKIN 10;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; COCULTURE; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; MEMBRANE BINDING; MESENCHYMAL STROMAL CELL; MESENCHYME CELL; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; STROMA CELL;

EID: 79954516117     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2010.542460     Document Type: Article

References (31)

1. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res. 2005;305:33-41. (Pubitemid 40380651)
2. Nasef A, Chapel A, Mazurier C, Bouchet S, Lopez M, Mathieu N, et al. Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T lymphocyte proliferation during cell contact with human mesenchymal cells. Gene Expr. 2007;13:217-26. (Pubitemid 47024153)
3. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2008;111:1327-33. (Pubitemid 351213419)
4. Campioni D, Moretti S, Ferrai L, Punturieri M, Castoldi GL, Lanza F. Immunophenotypic heterogeneity of bone marrowderived mesenchymal stromal cells from patients with hematologic disorders: correlation with bone marrow microenvironment. Haematologica. 2006;91:364-84.
5. Rizzo R, Campioni D, Stignani M, Melchiorri L, Bagnara GP, Bonsi L, et al. A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells. Cytotherapy. 2008;10:364-75. (Pubitemid 351983160)
6. Nasef A, Mathieu N, Chapel A, Frick J, Fran ç ois S, Mazurier C, et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation. 2007; 84:231-7.
7. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4- CD25 high FOXP3- regulatory T cells. Stem Cells. 2008;26:212-22.
8. Menier C, Rouas-Freiss N, Favier B, LeMaoult J, Moreau P, Carosella ED. Recent advances on the non-classical major histocompatibility complex class I HLA-G molecule. Tissue Antigens. 2010;75:201-6.
9. Rizzo R, Stignani M, Melchiorri L, Baricordi OR. Possible role of human leukocyte antigen-G molecules in human oocyte/embryo secretome. Hum Immunol. 2009;70:970-5.
10. Fournel S, Aguerre-Girr M, Huc X, Lenfant F, Alam A, Toubert A, et al. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8- cells by interacting with CD8. J Immunol. 2000;164: 6100-4. (Pubitemid 30408785)
11. Riteau B, Rouass-Freiss N, Menier C, Paul P, Dausset J, Carosella ED. HLA-G2,-G3 and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigenspecific CTL cytolysis. J Immunol. 2001;166:5018-26. (Pubitemid 32280714)
12. Lila N, Rouas-Freiss N, Dausset J, Carpentier A, Carosella ED. Soluble HLA-G protein secreted by allo-specific CD4- T cells suppresses the allo-prolifertaive response: a CD4- T cell regulatory mechanism. Proc Natl Acad Sci USA. 2001; 98:12150-5.
13. Ristich V, Liang S, Zhang W, Wu J, Horuzsko A. Tolerization of dendritic cells by HLA-G. Eur J Immunol. 2005;35: 1133-42. (Pubitemid 40542220)
14. Huang YH, Zozulya AL, Weidenfeller C, Schwab N, Wiendl H. T cell suppression by naturally occurring HLAG-expressing regulatory CD4- T cells is IL-10-dependent and reversible. J Leukoc Biol. 2009;86(2):273-81.
15. Carosella ED, Moreau P, Aractingi S, Rouas-Freiss N. HLA-G: a shield against inflammatory aggression. Trends Immunol. 2001;22:553-5. (Pubitemid 33016401)
16. Qiu J, Terasaki PI, Miller J, Mizutani K, Cai J, Carosella ED. Soluble HLA-G expression and renal graft acceptance. Am J Transplant. 2006;6:2152-6. (Pubitemid 44199549)
17. Pierdomenico L, Bonsi L, Calvitti M, Rondelli D, Arpinati M, Chirumbolo G, et al. Multipotent mesenchymal stem cells with immunosuppressive activity can be easily isolated from dental pulp. Transplantation. 2005;80:836-42. (Pubitemid 41443768)
18. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringd é n O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal cells. Exp Hematol. 2003;31:890-6. (Pubitemid 37211373)
19. Campioni D, Lanza F, Moretti S, Ferrari L, Cuneo A. Loss of Thy-1 (CD90) antigen expression on mesenchymal stromal cells from hematologic malignancies is induced by in vitro angiogenic stimuli and is associated with peculiar functional and phenotypic characteristics. Cytotherapy 2008; 10:69-82.
20. Campioni D, Rizzo R, Stignani M, Melchiorri L, Ferrari L, Moretti S, et al. A decreased positivity for CD90 on human mesenchymal stromal cells (MSCs) is associated with a loss of immnunosoppressive activity by MSCs. Citometry B Clin Citom. 2009;76:225-30.
21. Rizzo R, Mapp CE, Melchiorri L, Maestrelli P, Visentin A, Ferretti S, et al. Defective production of soluble HLA-G molecules by peripheral blood monocytes in patients with asthma. J Allergy Clin Immunol. 2005;115:508-13. (Pubitemid 40341703)
22. Rebmann V, Lemaoult J, Rouas-Freiss N, Carosella ED, Grosse-Wilde H. Report of the wet workshop for quantification of soluble HLA-G in essen. Hum Immunol. 2004;66:853-63. (Pubitemid 41416529)
23. Nagalakshmi ML, Murphy E, McClanahan T, de Waal Malefyt R. Expression patterns of IL-10 ligand and receptor gene families provide leads for biological characterization. Int Immunopharmacol. 2004;4:577-92. (Pubitemid 38553881)
24. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol. 2004;22:929-79. (Pubitemid 38680445)
25. Le Maux A, Noel G, Birebent B, Grosset JM, Vu N, De Guibert S, et al. Soluble human leucocyte antigen-G molecules in peripheral blood haematopoietic stem cell transplantation: a specific role to prevent acute graft-versus-host disease and a link with regulatory T cells. Clin Exp Immunol. 2008; 152:50-6. (Pubitemid 351347550)
26. Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS, et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant. 2010;in press.
27. Liu T, Wang Y, Tai G, Zhang S. Could co-transplantation of LPS derived hepatocytes and MSCs cure end stage liver disease? Cell Biol Int. 2009;33:1180-3.
28. Tyndall A, Uccelli A. Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. Bone Marrow Transplant. 2009;43:821-8.
29. Lanzoni G. Inflammatory bowel disease: moving toward a stem cell-based therapy. World J Gastroenterol. 2008;14: 4616-26.
30. Bocelli-Tyndall C, Bracci L, Spagnoli G, Braccini A, Bouchenaki M, Ceredig R, et al. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and autoimmune disease patients reduce the proliferation of autologous and allogeneic-stimulated lymphocytes in vitro. Rheumatology. 2007;46:403-8. (Pubitemid 46344649)
31. Newman RE, Yoo D, LeRoux MA, Danilkovitch-Miagkova A. Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug Targets. 2009;8:110-23.